Kimberly J. Long, a Ph.D. candidate in the Dalby Lab in the Division of Chemical Biology and Medicinal Chemistry, was a first author of a recent research paper published in the Proceedings of the National Academy of Sciences (PNAS).
College of Pharmacy Dean Sam Poloyac participated in a panel discussion from the 2023 Texas Leadership Society Luncheon on The University of Texas at Austin's bold pursuits in health and well-being. The discussion was moderated by UT President Jay Hartzell.
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.
The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded grants to six faculty members at UT Austin, including the Division of Chemical Biology and Medicinal Chemistry's Kevin Dalby, Ph.D. for his Targeted Therapeutic Drug Discovery and Development Program.
UT Pharmacy and UT Health Science Center San Antonio Assistant Professor Grace C. Lee, Pharm.D., Ph.D. is the first author of a recently published study that unveiled a novel concept, “immunologic resilience,” to accurately predict which COVID-19 patients will advance to severe disease and which will not.
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.
It is with great sadness that we announce the passing of Edward (Ted) Mills, Ph.D., associate professor in the Division of Pharmacology and Toxicology and Bergen Brunswig Corporation Centennial Fellow.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
